Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus

References

• Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23
   PubMed Web of Science ®Google Scholar
• Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13
   PubMed Web of Science ®Google Scholar
• Arauz-Pacheco C, Parrott MA, Raskin P. The treatment of hypertension in adult patients with diabetes (Technical Review). Diabetes Care 2002;25:134-47
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2002;25:199-201
   PubMed Web of Science ®Google Scholar
• Counteras F, Rivera M, Vasquez J, et al. Diabetes and hypertension physiopathology and therapeutics. J Hum Hypertens 2000;14:S26-S31
   PubMed Web of Science ®Google Scholar
• Reaven GM. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metabol 2003;88:2399-403
   PubMed Web of Science ®Google Scholar
• Arima H, Kiyohara Y, Kato I, et al. Alcohol reduces insulin–hypertension relationship in a general population: the Hisayama study. J Clin Epidemiol 2002;55:863-9
   PubMed Web of Science ®Google Scholar
• Lima NKC, Abbasi F, Lamendola C, et al. Prevalence of insulin resistance and related risk factors for cardiovascular disease in patients with essential hypertension. Am J Hypertens 2009;22:106-11
   PubMed Web of Science ®Google Scholar
• The Japanese Society of Hypertension Committee. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009;32:3-107
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension. Eur Heart J 2007;28:1462-536
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Barkris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2011. Diabetes Care 2011;34(Suppl 1):S11-S61
   PubMed Web of Science ®Google Scholar
• Japan Diabetes Society. Evidence-based practice guideline for the treatment of diabetes in Japan. Tokyo: Nankodo, 2010
   Google Scholar
• Kawamori R, Fujita T, Matsuoka H, et al. Relation between cardiovascular complications and blood pressure/blood glucose control in diabetic patients with hypertension receiving long-term candesartan cilexetil therapy: Challenge-DM study. Diabetes Res Clin Pract 2009;83:241-8
   PubMed Web of Science ®Google Scholar
• Japan Diabetes Society. Evidence-based practice guideline for the treatment of diabetes in Japan. Tokyo: Nankodo, 2004
   Google Scholar
• Japanese Society of Hypertension. Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypertens Res 2006;29(Suppl):S1-105
   PubMedGoogle Scholar
• Ogihara T, Nakao K, Fukui T, et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008;51:393-8
   PubMed Web of Science ®Google Scholar
• Nakao K, Hirata M, Oba K, et al. Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. Hypertens Res 2010;33:600-6
   PubMed Web of Science ®Google Scholar
• Kaku K, Daida H, Kashiwagi A, et al. Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. Curr Med Res Opin 2009;25:2925-32
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005;366:1279-89
   PubMed Web of Science ®Google Scholar
• Mogensen CE, Neldam S, Tikkannen I, et al. Randomized controlled trial of dual blockade of renin–angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-4
   PubMed Web of Science ®Google Scholar
• Saruta T, Hayashi K, Ogihara T, et al. Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study. Hypertens Res 2009;32:505-12
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Stafylas PC, Georgianos PI, et al. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am J Kidney Dis 2010;55:835-47
   PubMed Web of Science ®Google Scholar
• Nakamura T, Ushiyama C, Shimada N, et al. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications 2000;14:250-4
   PubMed Web of Science ®Google Scholar